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Background: As compared to cisplatin, trinuclear platinum compounds such as BBR3464 and DH6Cl have an
altered spectrum of activity possibly because they form long-range adducts with DNA as against mainly intrastrand
1,2-bifunctional adducts formed by cisplatin and its analogues. Because of the labilizing effect associated with the
trans-geometry, the compounds are expected to break down inside the cell thus serving to reduce the number of
long-range adducts formed. In contrast, trinuclear platinum complexes with cis-geometry for the terminal metal
centres would be less subject to such breakdown and hence may produce a greater number of long-range
inter- and intrastrand adducts with the DNA. This paper describes the synthesis and activity against human ovarian
tumour models of of three new trinuclear platinum complexes with cis-geometry for terminal platinum centres,
coded as QH4, QH7 and QH8. The paper also describes cellular accumulation of platinum, level of drug−DNA
binding, and nature of interaction of the compounds with pBR322 plasmid DNA.
Results: Methods of synthesis, elemental analysis, spectral studies and molar conductivity measurements provide
support to the suggested structures of the compounds. QH4 and QH8 are found to be more cytotoxic than
cisplatin against the parental A2780 cell line; QH8 is more active than cisplatin against the resistant A2780cisR and
A2780ZD0473R cell lines as well. The least compound QH7 shows a greater activity against the resistant cell lines than
the parental cell line; it is most damaging to pBR322 plasmid DNA and most able to induce changes in DNA
conformation. The variations in activity of the compounds, changes in intracellular drug accumulation and levels of
Pt−DNA binding with the changes in number of planaramine ligands bound to central platinum and the length of
the linking diamines, can be seen (1) to illustrate structure-activity relationships and (2) to highlight that the
relationship between antitumour activity and interaction with cellular platinophiles including DNA can be quite
complex as the cell death is carried out by downstream processes in the cell cycle where many proteins are
involved.
Conclusion: Among the three designed trinuclear platinum complexes with cis-geometry for the terminal metal
centres, the most active compound QH8 is found to be more active than cisplatin against the parental A2780 and
the resistant A2780cisR and A2780ZD0473R cell lines.
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Figure 1 Structures of QH4, QH7 and QH8. QH2: [{cis-PtCl(NH3)2}
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Although cisplatin is a widely used anticancer drug [1,2],
its use is also limited due to intrinsic and/or acquired re-
sistance and the presence of numerous side effects [3,4].
Trinuclear platinum compounds such as BBR3464, DH6Cl,
DH7Cl, TH1 and CH25 that bind with DNA differently
than cisplatin (in the sense that they form long-range
adducts with DNA as against mainly 1,2-bifunctional
adducts formed by cisplatin) are found to be signifi-
cantly more cytotoxic than cisplatin [5-9]. Because of
the trans-geometry for the terminal metal centres, the
compounds are expected to break down inside the cell,
thus reducing the number of long-range adducts with
DNA. The degradation products are expected to bind
with cellular thiols such as glutathione that plays key
roles in detoxification of reactive oxygen and reactive
nitrogen species. In contrast, trinuclear platinum com-
plexes with cis-geometry for the terminal metal centres
would be less subjected to such breakdown and there-
fore may produce a greater number of long-range inter-
and intrastrand adducts with DNA. The present paper
deals with the synthesis, characterization and activity of
three new trinuclear platinum complexes with cis-geometry
for terminal platinum centres, [{cis-PtCl(NH3)2 μ-{trans-Pt
(3-hydroxypyridine)2(H2N(CH2)4NH2)2}]Cl4 (coded as QH
4), [{cis-PtCl(NH3)2}2 μ-{trans-Pt(3-hydroxypyridine)(NH3)
(H2N(CH2)6NH2)2}]Cl4 coded as QH7 and [{cis-PtCl
(NH3)2}2 μ-{trans-Pt(3-hydroxypyridine)(NH3)(H2N(CH2)
4NH2)2}] coded as QH8 (Figure 1). Whereas the two
terminal platinum ions bind covalently with DNA, the
central platinum ion can only undergo non-covalent inter-
actions including electrostatic interaction and hydrogen
bonding via 3-hydroxypyridine ligand.
Methods
Materials
3-hydroxypyridine, N,N-dimethylformamide [DMF], di-
methyl sulfoxide (DMSO), 1,6-diaminohexane dihy-
drochloride and putrescine (tetramethylene diamine)
(Sigma Chemical Company St. Louise USA); potassium
tetrachloroplatinate(II) (K2[PtCl4]), restriction enzyme
(BamH1), 10X digestion buffer and Polaroid black-and-
white print film type 667, trypsin, hepes, dulbecco,s
phosphate buffered saline (PBS) powder, 3-[4,5-dimeth-
ylthiazol-2yl]-diphenyl tetrazoliume bromide (MTT) and
dimethyl sulfoxide (DMSO) (Aldrich Pty Ltd NSW,
Australia); dihydrochloride, sodium hydroxide, silver ni-
trate (AgNO3), potassium chloride (KCl), potassium iod-
ide (KI) ethanol, methanol, acetone, diethyl ether and
concentrated hydrochloric acid (HCl) (Alax chemicals
Auburn NSW Australia); concentrated ammonia solu-
tion, triethyl amine, dichloromethane and 28% ammonia
solution (Asia Pacific Speciality Chemicals Ltd Auckland
New Zealand); agarose and pBR322 plasmid DNA (ICNBiomedicals Ohio USA); trizma-HCl, trizma base diso-
dium salt of ethylene diamine tetraacetic acid, boric acid,
acetic acid and ethidium bromide (Sigma USA); fetal calf
serum, 5X RPMI 1640, 200 mM L-glutamine and 5.6%
sodium bicarbonate (Trace Bioscience Pty Ltd Australia);
commercially available JETQUICK Blood DNA Spin Kit/
50 (Astral Scientific Australia).
Synthesis
CH1denoting [trans-PtCl2(3-hydroxypyridine)2 required
for the synthesis of QH4 and YH11denoting [trans-
PtCl2(NH3)(3-hydroxypyridine)] required for the synthe-
sis of QH7 and QH8 were prepared according to
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prepared following a method similar to that used for the
synthesis of TH1 [7]. The method used for synthesis of
QH4 was essentially same as that used for the synthesis
of QH8 except that CH1 was used instead of YH11. The
schemata for synthesis of QH4, QH7 and QH8 are given
in Figures 2, 3 and 4 respectively.
Briefly, cisplatin (0.5 mmol, 0.15 g) was dissolved in
10 mL of DMF to which was added 0.495 mmol of silver
nitrate (0.0849 g). The mixture was stirred at room
temperature for 24 h in the dark and then centrifuged
(at 4800 rpm for 30 min, 21°C) to remove precipitate of
AgCl. The supernatant containing a solution of cis-Pt
(NH3)2Cl(DMF) was collected and kept at −16ºC. A sus-
pension of 0.25 mmol (0.0945 g) of YH11 or 0.25 mmol
(0.114 g) of CH1 in 10 mL of DMF was gently heated
with stirring at 60°C for 20 min. In the case of QH4 and
QH8 0.5 mmol of 1, 4-diaminobutane dihydrochloride
(0.085 g) was dissolved in 4 mL of DMF and in the case
of QH7 0.5 mmol of 1, 6-diaminohexane (0.058 g) was
dissolved in 4 mL of DMF to which 1 mL of 1 M HCl


































Figure 2 Schema for the synthesis of QH4.was stirred for a further 15 min. It was then added to
YH11 suspension dropwise with stirring within 30 min
of its preparation followed by the addition of 0.5 mL of
1 M NaOH with stirring at 70°C. Stirring was continued
at 60°C for about 1 h, then for 4 h at 50°C followed by
the addition of 200 μL of 1 M NaOH. The mixture was
stirred for further 5 min at 50°C to which was added cis-
platin supernatant (0.25 mmol) with stirring. The
temperature of the mixture was increased to 70°C and
stirred for a further 5 min. A further 200 μL of 1 M
NaOH was added to the resulting mixture followed by
the addition of a further 0.25 mmol of cisplatin super-
natant. The mixture was left standing while being stirred
at 60°C for 50 min and then for 15 days at room
temperature. The volume of the filtrate was reduced to
4 mL using a vacuum concentrator consisting of Javac
DD150 Double stage High Vacuum Pump Savant RVT
4104 Refrigerated Vapor Trap and Savant Speed Vac 110
Concentrator. About 20 mL of dichloromethane was
added to the concentrated solution. The mixture was left
standing at 5°C for 6 h. The light yellow precipitate pro-
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Figure 3 Schema for the synthesis of QH7.
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air-dried. The steps in synthesis are shown in Figures 3
and 4. Attempts were also made to increase the purity of
the compounds by repeated dissolution in DMF followed
by precipitation with dichloromethane. However, the
best results were obtained when crude products were re-
peatedly washed with 95% ethanol:5% water mixture.
Characterization
Microanalyses
C, H, and N were determined using a Carlo Erba 1106
automatic analyzer available at the Australian National
University whereas Pt was determined by graphite furnace
atomic absorption spectroscopy (AAS). As QH4, QH7
and QH8, could not be obtained in crystalline form, IR,
MS and 1H NMR spectra were used to aid in structural
characterization. The IR spectra were obtained using aVarian FT-IR spectrometer (Bruker IFS66 spectrometer).
To obtain mass spectra, solutions of QH4, QH7 and
QH8 made in 90% methanol and 10% DMF were
sprayed into a Finnigan LCQ mass spectrometer. To ob-
tain 1H NMR spectra using a Bruker DPX400 spectrom-
eter at 400.2 MHz. QH4 was dissolved in DMF, QH7 in
CDCl3 and QH8 in D2O/DMF and prepared in 5 mm
high precision Wilmad NMR tube. Spectra were refer-
enced to internal solvent residues and all the spectra
were recorded at 300 K (±1 K).
QH4 Yellow powder, 1H NMR (400 MHz, [D6] DMSO): δ
(ppm) = 8.5 (CH ortho), 7.5 (CH meta), 4.2 (NH3-Pt), 3.5
(water dissolved in DMF), 2.9 (NH2-Pt), 2.6 (DMSO), 2.2
(CH2), 1.8 (CH2); IR (KBr): 3278.7, 3207.5, 3078.6, 2788.4,
2444.7, 1618, 1468.0, 1347.3, 1282.9, 1111.9, 1022.2, 808.0,




























































Figure 4 Schema for the synthesis of QH8.
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(M+ 3H), 1289 (35) = [Pt3(3-hydroxypyridine)2(NH2(CH2)
4NH2)3(NH3)3Cl2 + 4Cl], 859.85 (53) = [Pt2(3-hydroxypyri-
dine) (NH2(CH2)4NH2)2(NH3)Cl3 + 3Cl + 5H], 452.98 (10
0) = [Pt(3-hydroxypyridine)2(CH3NH2)Cl +H], 388 (64) =
[Pt(NH2(CH2)4NH2) (NH3)2Cl + Cl].
Anal. calcd for C18H46Cl6N10O2Pt3: C 17.6, H 3.8, N
11.4, Cl 17.3, Pt 47.5; found: C 17.3 ± 0.4, H 3.9 ± 0.4, N
11.7 ± 0.4, Cl 17.6 ± 0.4, Pt 47.1 ± 1.0.QH7 Light yellow powder, 1H NMR (400 MHz, [D6]
DMSO): δ (ppm) = 8.5 (CH ortho), 8.25 (CH ortho), 7.9
(CH meta), 7.6 (CH para), 5.35 (NH), 4.4 (CH2-N), 3.2
(CH2), 2.8 (CH2), 1.8 ( CH2), δ =1.5 (CH2); IR (KBr):
3278.7, 3207.5, 3078.6, 2788.4, 2444.7, 1618, 1468.0,
1347.3, 1282.9, 1111.9, 1022.2, 808.0, 693.2, 501.5,
447.4 cm−1; MS (ESI) m/z (%): 15226 (15226/2 = 763)
(1.00) = [Pt3(3-hydroxypyridine)5(NH2(CH2)6NH2)2(NH3)
Cl2 + 4Cl + 4H], 479.25 (50) = [Pt (3-hydroxypyridine)
(pyridine)(NH2(CH2)6NH2) – 6H], 459.18 (30) = [Pt(3-
hydroxypyridine) (NH2(CH2)6NH2)Cl2 – 2H].Anal. calcd for C17H52Cl6N10OPt3: C 16.9, H 4.3, N
11.6, Cl 17.6, Pt 48.3; found: C 17.0 ± 0.4, H 4.6 ± 0.4, N
11.6 ± 0.4, Cl 17.5 ± 0.4, Pt 48.8 ± 1.0.QH8 Greenish yellow powder, 1H NMR (400 MHz, [D6]
DMSO): δ (ppm) = 8.4 (CH ortho), 7.5 (CH meta), 4.8
(NH3-Pt), 3.5 (water dissolved in DMF), 3.0 (NH2-Pt),
2.6 (CH2), 2.2 (CH2), 1.8 (CH2); IR (KBr): 3277.3, 3192.3,
2988.0, 2776.6, 2360.8, 1595.8, 1449.7, 1316, 1299.5,
1114.1, 1017.4, 803.8, 692.4, 553.6, 486.1, 420.7; MS
(ESI) m/z (%): 1276 (1276/2 = 638) (40) = [Pt3(3-hydro-
xypyridine)4 (NH2(CH2)4NH2)2(NH3)2Cl3], 675.96 (675.9
6/2 = 338) (90) = [Pt2(3-hydroxypyridine)(NH2(CH2)4NH2)
Cl2 – 4H], The peak at m/z = 671 corresponds to [Pt2
(NH2(CH2)4NH2) (NH2(CH2)4)(NH3)3Cl2], 430 (85) = [Pt
(3-hydroxypyridine)(NH2(CH2)4NH2)(NH3)Cl – H], 389
(93) =Pt(NH2(CH2)4NH2)Cl3, 372 (97) = [Pt(NH2(CH2)4NH2)
(NH3)Cl2 +H].
Anal. calcd for C18H46Cl6N10O2Pt3: C 13.5, H 3.8, N
12.1, Cl 18.4, Pt 50.7; found: C 13.8 ± 0.4, H 4.1 ± 0.4, N
11.9 ± 0.4, Cl 18.4 ± 0.4, Pt 49.9 ± 1.0.
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mol−1 of QH2, QH3 and QH4 are respectively 336.0,
856.0 and 384.0.
Cytotoxicity assays
Cytotoxicity of QH4, QH7, QH8 and cisplatin (used as a
reference) against human ovarian cancer cell lines,
cisplatin-sensitive A2780, cisplatin-resistant A2780cisR
and ZD0473-resistant A2780ZD0473R was determined
using MTT (3-(4,5–Di-methyl-2-thiazole)-2,5-diphenyl-
2H-tetrazolium bromide) reduction assay [11,12]. About
4000 to 5500 cells (maintained in logarithmic growth
phase in complete medium consisting of RPMI 1640,
10% heat-inactivated fetal bovin serum (FBS), 20 mM
hepes, 0.112% sodium bicarbonate, and 2 mM glutamine
without antibiotics) were seeded into flat-bottomed 96-
well culture plates in 10% FBS/RPMI 1640 culture
medium. Platinum complexes dissolved first in a mini-
mum volume of DMF were diluted to the required con-
centrations with mQ water and filtered to sterilize. Serial
dilutions ranging from 0.16 μM to 20 μM in 10% FCS/
RPMI 1640 medium were prepared and added to equal
volumes of cell culture in quadruplicate wells. The IC50
values (drug concentrations required for 50% cell kill)
were obtained from the results of triplicate determina-
tions of at least three independent experiments.
Cellular platinum accumulation and platinum − DNA
binding
The method used for the determination of cellular accu-
mulation of platinum and the level of platinum-DNA
binding was a modification of the method described by
Di Blasi et al. [12]. In short, exponentially growing
A2780, A2780cisR and A2780ZD0473R cells (cell density =
1 × 106 cells mL−1) were incubated with solutions of
QH4, QH7, QH8 and cisplatin (at 50 μM final concen-
tration) for 2 h, 4 h and 24 h at the end of which cell
monolayers were trypsinized and cell suspension (5 mL)
was transferred to centrifuge tubes and spun at
3500 rpm for 2 min at 4°C. Ice-cold phosphate-buffered
saline (PBS) was used to wash the cells twice and the
pellets were stored at −20°C until assayed. At least three
independent experiments were performed. For the deter-
mination of drug accumulation in the cells, cell pellets
were suspended in 0.5 mL 1% triton-X, held on ice then
sonicated (5 min). Total platinum contents in cell pellets
were determined by graphite furnace AAS. At least three
independent experiments were performed as was done
for DNA binding studies.
Platinum − DNA binding
Following incubation of cells with drugs, high molecular
weight DNA was isolated from cell pellet using JETQUICK
Blood DNA Spin Kit/50 according to the modified protocolof Bowtell et al. [13]. DNA content was determined by
UV spectrophotometry (260 nm). Pt levels were deter-
mined by graphite furnace AAS [14]. A260/A280 ratios were
found to be between 1.75 and 1.8 for all samples ensuring
its high purity of the DNA and the DNA concentration
was calculated according to the following equation: Con-
centration = Absorbance at 260 nm× 50 ng/μL.
Interaction with pBR322 plasmid DNA
Interaction between QH4, QH7, QH8 and cisplatin with
pBR322 plasmid DNA, with and without BamH1 digestion,
was studied out using gel electrophoresis based on a
method described by Stellwagen [15]. The amount of DNA
was kept constant while the concentrations of compounds
were varied. Exactly, 1.5 μL of supplied pBR322 plasmid
DNA in solution was added to solutions of the compounds
at different concentrations ranging from 0.55 μM to
70 μM for QH4, QH8 and cisplatin. For QH7 concentra-
tion ranged from 0.12 μM to 15 μM. The samples were
incubated for 4 h on a shaking water bath at 37°C. The re-
action was stopped by rapid cooling to 0°C for 20 min. The
samples were mixed with 1 μL of marker dye ethidium
bromide. 16 μL of each sample was loaded onto 1% agarose
gel made in TAE buffer. The gel was photographed using
Eastman Kodak Company, Molecular Imaging Systems.
BamH1 restriction enzyme digestion
BamH1 is a type II restriction endonuclease that hy-
drolyses the phosphodiester bonds. It binds at the recog-
nition sequence 5′-GGATCC-3′, and chops these
sequences just after the 5′-guanine on each strand [16].
pBR322 plasmid DNA contains a single restriction site
for BamH1 that converts the supercoiled form I and sin-
gly nicked circular form II to linear form III DNA. An
identical set of drug-DNA mixtures as that described
previously, was first incubated for 4 h on a shaking
water bath at 37°C and then subjected to BamH1 (10
units μL−1) digestion. The mixtures were left in a shak-
ing water bath at 37°C for another 1 h at the end of
which the reaction was terminated by rapid cooling.
4 μL of ethidium bromide was added to each sample be-
fore loading onto the gel. The gel was photographed fol-
lowing the method described previously.
Results and discussion
Synthesis and characterization
The structure of QH4, Q73 and QH8 could not be con-
firmed by single crystal x-ray diffractometry as no suit-
able single crystal could be grown. However, the results
of elemental analyses and spectral studies (described
earlier) can be seen to provide support for the suggested
structures of the compounds (Figure 1). More import-
antly, step-up method of synthesis starting from the cen-
tral unit essentially ensures that the targeted compound
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trinuclear platinum complexes [6-9].
Activity against ovarian cancer cell lines
Table 1 list the IC50 values and resistance factors (RF)
for QH4, QH7, QH8 and Cisplatin as applied to the hu-
man ovarian A2780, A2780cisR and A2780ZD0473R cancer
cell lines. IC50 values are defined as drug concentrations
required for 50% cell kill and RF is defined as the ratio
of the concentration of drug required for 50% cell kill in
the resistant cell line to that in the parent cell line.
It can be seen that QH4 and QH8 are more active than
cisplatin against the parental A2780 cell line. QH8 is more
active than cisplatin against the resistant A2780cisR as well.
Although QH7 is less active than cisplatin against all the
three cell lines, it has a greater activity against the resistant
A2780cisR and A2780ZD0473R cell lines than the parental
A2780 cell line so that it has resistant factors less than
one (0.73 and 0.52 for QH7 as against 8.08 and 3.95 for
cisplatin). The results indicate that at the level of its activity,
QH7 has been better able to overcome resistances operat-
ing in both A2780cisR and A2780ZD0473R cell lines. Although
QH4 and QH8 have comparable activity against the paren-
tal A2780 cell line, QH4 has much lower activity than QH8
against the resistant A2780cisR cell line. This difference in
activity against the resistant cell line is likely to be associ-
ated with non-covalent interactions with the DNA.
Whereas the central platinum ion in QH4 is bonded
to two 3-hydroxypyridine ligands, it is bonded to one
3-hydroxypyridine and one ammino ligand in QH8. With
the idea that in binding with DNA, QH4 would experience
a greater steric hindrance than QH8, one would expect a
lower level of Pt−DNA binding from interaction with QH4
than with QH8. It will be seen later that the converse is the
case, possibly highlighting the role of DNA repair in cyto-
toxicity and the level of Pt−DNA binding.
Cellular accumulation
Figure 5 gives the total intracellular platinum levels
(expressed as nanomoles Pt per 2x106 cells) found inTable 1 IC50 (μM) values and RFs for compounds against
A2780, A2780cisR, A2780ZD0473R cell lines
Compounds IC50
[a]
A2780 A2780cisR RF[b] A2780ZD0473R RF[c]
Cisplatin 1.09 ± 0.06 8.08 ± 1.03 7.45 4.28 ± 0.33 3.95
QH4 0.62 ± 0.11 9.24 ± 0.53 14.91 5.22 ± 0.21 8.42
QH7 8.87 ± 0.01 6.45 ± 0.47 0.73 4.61 ± 0.46 0.52
QH8 0.55 ± 0.02 4.48 ± 0.49 8.15 4.41 ± 0.22 8.02
[a]IC50 values are drug concentrations required for 50% cell death and are the
means ± SD from quadruplicate determinations of at least three independent
experiments. [b]RF standing for resistant factor is the ratio of IC50 value in
resistant cell line to that in the parent cell line. [c]RF resistant factor applying
to the cell lines A2780 and A2780ZD0473R.A2780, A2780cisR and A2780ZD0473R cells after their ex-
posure to 50 μM concentrations of QH4, QH7, QH8
and cisplatin for 2, 4 and 24 hours.
When platinum accumulations from cisplatin, QH4,
QH7 and QH8 are compared, it is found that all the three
trinuclear compounds QH4, QH7 and QH8 result in
higher platinum accumulation than cisplatin at all time
points. The results indicate that the carrier-mediated
transport of QH4, QH7 and QH8 must be faster than the
overall transport of cisplatin by both diffusion and the use
of carriers. Surprisingly the least active compound is asso-
ciated with the highest Pt accumulations in all the three
cell lines at all time points, indicating that there is no clear
relationship between activity and cellular accumulation of
QH4, QH7 and QH8.
DNA binding
Figure 6 gives the levels of platinum−DNA binding
expressed as nanomol of Pt per milligram of DNA from
QH4, QH7, QH8 and cisplatin in A2780, A2780cisR and
A2780ZD0473R cells as a function of time.
Among the three designed complexes, QH8 was found
to be associated with the highest Pt−DNA binding levels
at 2 h and 4 h but lowest at 24 h in all the three cell
lines. At 2 h, QH8 had the highest level of Pt−DNA
binding in A2780 cell line. The actual orders of Pt−DNA
binding were:
At 2 h:
A2780 cell line: QH8 > Cisplatin > QH4 > QH7
A2780cisR cell line: QH8 > Cisplatin > QH7 > QH4
A2780ZD0473R cell line: QH8 >QH4 >QH7 > Cisplatin
At 4 h:
A2780 cell line: QH8 > Cisplatin > QH7 > QH4
A2780cisR cell line: QH8 > Cisplatin > QH7 > QH4
A2780ZD0473R cell line: QH8 >QH7 > Cisplatin > QH4
At 24 h:
A2780 cell line: QH7 > Cisplatin > QH4 > QH8
A2780cisR cell line: QH7 >QH4 >QH8 > Cisplatin
A2780ZD0473R cell line: QH7 >QH4 >QH8 > Cisplatin.
The results indicate that at least initially QH8 binds
most readily with DNA in all the three cancer cell lines.
However, whereas the binding of QH8 with nuclear
DNA reaches saturation early, binding of QH4 and QH8
continues to increase such that at the end of 24 h they
have overtaken QH8 in terms of Pt−DNA binding levels.





























































QH4 QH7 QH8 Cisplatin
2Hr 4Hr 24hr
A2780ZD473R
Figure 5 Total intracellular platinum levels (expressed as nmol Pt per 2x106 cells) found in A2780, A2780cisR and A2780ZD0473R cells
after their exposure to 50 μM concentrations of QH4, QH7, QH8 and cisplatin for 2, 4 and 24 hours.
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A2780cisR cell line: QH7 >QH4 >QH8 > Cisplatin
A2780ZD0473R cell line: QH7 >QH4 >QH8 > Cisplatin.
For QH8, the levels of Pt−DNA binding at 24 h in the
resistant A2780cisR and A2780ZD0473R cell lines are actu-
ally less than the corresponding values at 4 h, suggesting
that increased DNA repair must be in play as applied to
the adducts formed by QH8. This is in line with the idea
that increased DNA repair is a dominant mechanism of
resistance operating in resistant cancer cell lines [17]. It
was noted earlier that the least active compound QH7
had a greater activity against the resistant A2780cisR andA2780ZD0473R cell lines than the parental A2780 cell line
whereas QH4 and QH8 had lower activity against the re-
sistant cell lines than that against the parental cell line.
It can be seen that for QH7 the level of Pt−DNA binding
at 24 h is greatest for the A2780ZD0473R cell line and
least for the parental A2780 cell line. This can be seen
to be in line with the order of activity of the compound.
In contrast, the level of Pt−DNA binding at 24 h for
QH4 is greatest in the parental A2780 cell line than the
values in the resistant cell lines. As for QH8, whereas
the level of Pt−DNA binding in the parental cell line
continued to increase with time the values in the resist-
































































2 h - 4 h - 24 h - 
A2780ZD0473R
Figure 6 Levels of platinum-DNA binding expressed as nmol Pt per milligram of DNA from QH2, QH7, QH8 and cisplatin in A2780,
A2780cisR and A2780ZD0473R cells as a function of time.
Hamad et al. Journal of Biomedical Science 2014, 21:41 Page 9 of 12
http://www.jbiomedsci.com/content/21/1/41values at 2 and 4 h. It is possible that DNA repair pro-
cesses became more significant with time in the case of
QH4 and QH8 than for QH7. It is also appropriate to
note that besides having highest Pt−DNA binding levels
at 24 h in all the three cell lines, QH7 was associated
with highest cellular accumulation of platinum at all
time points. It is suggested that the longer linker chain
in QH7 (six carbons in QH7 as against four carbons in
QH4 and QH8) can make it more hydrophobic so that it
would bind more efficiently to hydrophobic pocket of
the carrier molecule and that it was more suited to formlong-range interstrand adducts with DNA based on dis-
tance match [18].
Interaction with pBR322 plasmid DNA
When pBR322 plasmid DNA was interacted with in-
creasing concentrations of QH4, QH7, QH8 and cis-
platin, generally two DNA bands corresponding to forms
I and II were observed in both untreated and treated
pBR322 plasmid DNA (Figure 7).
As the concentration of the compounds was increased,
the mobility of both forms I and II bands increased but
QH4 QH7
QH8 Cisplatin
Figure 7 Electrophotograms applying to the interaction of pBR322 plasmid DNA with increasing concentrations of QH4, QH7, QH8 and
cisplatin. Lane B applied to untreated pBR322 plasmid DNA to serve as a control, lanes 1 to 8 applied to plasmid DNA interacted with increasing
concentrations of the compounds and cisplatin. The concentrations for QH4, QH8 and cisplatin were: lane 1: 0.55 μM, lane 2: 1.09 μM, lane 3:
2.19 μM, lane 4: 4.38 μM, lane 5: 8.75 μM, lane 6: 17.50 μM, lane 7: 35.00 μM, and lane 8: 70.00 μM. The concentrations for QH7 is as follows lane
1: 0.12 μM, lane 2 : 0.23 μM, lane 3: 0.47 μM, lane 4: 0.94 μM, lane 5:1.88 μM, lane 6: 3.75 μM, lane 7: 7.50 μM and lane 8: 15.00 μM.
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bands first decreased in the case of QH4, QH8 and cis-
platin. The change in mobility was less significant in the
case of QH7 although it was most damaging to the
DNA as compared to QH4 and QH8. In the case of
QH8, the separation between the bands was smallest at
4.38 μM (lane 4) above which separation was greater
(lanes 5 and 6). In the case of cisplatin also, a faint coa-
lesced band could be seen at 35.00 μM (lane 7) and no
DNA band was present at 70.00 μM (lane 8). The ap-
pearance of a coalesced band followed by the presence
of two distinct or nearly distinct bands at higher concen-
tration indicates the change in the conformation of the
form I DNA from being negatively supercoiled form I
though relaxed circular form I to positively super coiled
form I [18]. A single but faint coalesced band observedQH4
QH8
Figure 8 Electrophoretograms applying to the incubated mixtures of
QH8 and cisplatin followed by digestion with BamH1. Lane B1 applied
lane B2 applied to untreated but digestion with BamH1. Lanes 1 to 8: apply
the compounds followed by BamH1 digestion. The concentrations for QH4
2.19 μM, lane 4: 4.38 μM, lane 5: 8.75 μM, lane 6: 17.50 μM, lane 7: 35.00 μM
1: 0.12, lane 2 : 0.23, lane 3: 0.47, lane 4: 0.94, lane 5:1.88, lane 6: 3.75, lane 7at still higher concentrations of QH8 (7.50 μM and
15.00 μM applying to lanes 7 and 8) possibly is indica-
tive of DNA damage rather than any change in DNA
conformation. The most active compound QH4 can be
seen to be slightly more damaging to DNA than QH8
but less than QH7.BamH1 digestion
To gain further insight into changes in DNA confirmation,
drug-DNA incubation as above was followed by BamH1
digestion. Figure 8 gave the electrophoretograms applying
to the interaction of pBR322 plasmid DNA with increas-
ing concentrations of QH4, QH7, QH8 and cisplatin for a
period of 4 h at 37°C followed by BamH1 digestion for a
further period of 1 h at the same temperature.QH7
Cisplatin
pBR322 plasmid DNA and varying concentrations of QH4, QH7,
to the untreated pBR322 plasmid DNA and undigested with BamH1,
to pBR322 plasmid DNA interacted with increasing concentrations of
, QH8 and cisplatin were: lane 1: 0.55 μM, lane 2: 1.09 μM, lane 3:
, and lane 8: 70.00 μM. The concentrations for QH7 is as follows lane
: 7.50 and lane 8: 15.00.
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(B2), only one band corresponding to form III band was
observed whereas in the untreated and undigested
pBR322 plasmid DNA (B1). In the case of QH4, three
bands corresponding to forms I, II and III were observed
in lanes 1, 2 and 3 applying to concentrations 0.55 μM,
1.09 μM and 2.19 μM respectively. Two bands were ob-
served in lanes 4, 5 and 8 applying to concentrations
4.38 μM, 8.75 μM and 70.00 μM respectively. The appear-
ance of three bands in lanes 6 and 7 corresponding to
concentrations 17.50 μM and 35.00 μM respectively, is
possibly an artifact of the presence of excess enzyme. In
the case of QH7, three bands corresponding to forms I, II
and III were observed in lane 1 corresponding to the con-
centration 0.12 μM. Two bands corresponding to forms I
and II were observed in lanes 2 to 5 for concentrations
ranging from 1.09 μM and 8.75 μM and a single faint
could be seen in lane 6 corresponding to concentration
17.50 μM. No band can be seen in lanes 7 and 8. In the
case of QH8, three bands corresponding to forms I, II and
III were observed in lanes 1 and 2, and only forms I and II
bands were observed in lanes 3 to 8. The results indicate
that among the designed complexes, QH7 is most able to
induce changes in DNA conformation and to cause most
DNA damage even though it is less active, in fact the least
active compound against the parent cell line A2780. The
lower activity of QH7 but a greater ability to cause DNA
damage and induce changes in DNA conformation can be
seen to highlight complex nature of the relationship be-
tween drug−DNA binding and activity. It may be noted
that whereas binding of platinum drug with DNA brings
about changes in DNA conformation and can induce
DNA damage, cell death through apoptosis is actually car-
ried out by downstream processes in the cell cycle in
which many proteins are involved. In the case QH8, three
bands corresponding to forms I, II and III were observed
in lanes 1 and 2 corresponding to the concentrations
0.55 μM and 1.09 μM respectively, two bands correspond-
ing to forms I and II were observed in lanes 3 to 6 for con-
centrations ranging from 2.19 μM to 17.50 μM and a
much fainter band could be seen in lane 7 correspondingTable 2 Bands observed after BamH1 digestion of
pBR322 plasmid DNA interacted with increasing
concentrations of compounds
Compounds Bands observed in lanes 1 to 8
1 2 3 4 5 6 7 8
QH4 I, II, III I, II, III I, II, III I, II I, II I, II, III I, II, III I, II
QH7 I, II, III I, II, III I, II I, II I, II I, II I,II No band
QH8 I, II, III I, II, III I, II I, II I, II I, II I,II No band
Cisplatin I, II, III I, II I, II I, II I, II I, II I,II No band
The numbers I, II and III stand respectively for supercoiled form I DNA, singly
nicked circular form II DNA and linear form III DNA.to concentration 35.00 μM. No band can be seen in lane
8. In the case of cisplatin, three bands corresponding to
forms I, II and III were observed in lane 1 corresponding
to the concentration 0.55 μM and two bands correspond-
ing to forms I and II were observed in lanes 2 to 7 corre-
sponding to concentrations ranging from 1.09 μM, to
35.00 μM. No band can be seen in lane 8. Table 2 gives
provides a list of the bands.
Conclusion
Three triplatinum complexes with cis-geometry for ter-
minal metal centres and coded as QH4, QH7 and QH8
have been synthesized and investigated for activity
against ovarian tumour models. QH8 has been found to
be more active than cisplatin against parental and resist-





DH6Cl: [{trans-PtCl(NH3)2}2 μ{trans-Pt(NH3)2(H2N(CH2)6NH2)2}]Cl4; YH11: [trans-
PtCl2(NH3)(3-hydroxypyridine)]; CH1: [trans-PtCl2(3-hydroxypyridine)2;
MTT: 3-[4,5-dimethylthiazol-2yl]-diphenyl tetrazolium bromide;
DMF: N,N-dimethylformamide; DMSO: Dimethyl sulfoxide (DMSO).
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